SuperworthAlumis EPS ALMS
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$3.80
- Latest quarter, Q2 FY26
- −$1.11
- −244% on a year earlier
- Fiscal year 2025
- −$3.00
Alumis' earnings per share was −$3.80 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.11, down 244% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.00 | n/a |
| FY2024 | −$47.61 | n/a |
| FY2023 | −$72.11 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.11 | −244% | −$3.80 | |
| Q1 FY26 | −$0.74 | n/a | −$1.92 | |
| Q4 FY25 | −$0.89 | n/a | −$3.00 | |
| Q3 FY25 | −$1.06 | n/a | −$3.86 | |
| Q2 FY25 | $0.77 | n/a | −$4.53 | |
| Q1 FY25 | −$1.82 | n/a | −$28.40 | |
| Q4 FY24 | −$1.75 | n/a | −$47.61 | |
| Q3 FY24 | −$1.73 | n/a | −$63.05 | |
| Q2 FY24 | −$23.10 | n/a | −$81.08 | |
| Q1 FY24 | −$21.03 | n/a | −$75.11 | |
| Q4 FY23 | −$17.19 | n/a | −$72.11 | |
| Q3 FY23 | −$19.76 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Alumis' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ALMSAlumis | −$3.80 | |
| ABUSArbutus Biopharma | $0.78 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| Peer median | $1.08 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Alumis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.